



July 2009

Dear Valued Customer:

Due to low customer demand, effective 7PM on August 31st, 2009, Merck & Co., Inc., will discontinue packages of GARDASIL[®] [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] 5-mcg/0.5-mL prefilled syringes **with the UltraSafe Passive^{®a} delivery system.**

NDC Code	Package Description	Description
0006-4109-06	Box of 6 prefilled syringes with the UltraSafe Passive ^{®a} delivery system	1 x 6 syringes

Merck will continue to manufacture and distribute the following packages of GARDASIL:

NDC Code	Package Description	Description	Price
0006-4045-00	Single-dose 0.5-mL vial	1 x 1 vial	\$129.79
0006-4045-41	Box of 10 single-dose 0.5-mL vials	1 x 10 vials	\$1,295.22
0006-4109-09	Single-dose 0.5-mL/6x syringes	Box of 6 single-dose syringes	\$786.25

This packaging change will allow Merck to better meet the increasing vaccine demands in a more cost-efficient manner.

We appreciate your understanding with this change. If you should have questions, please call the Merck Vaccine Customer Center at 1-877-VAX-MERCK (1-877-829-6372). For direct purchase customers who are wholesalers and physician distributors, please contact your National Account Director or call the Order Management Center at 1-800-MERCK-RX (1-800-637-2579).

Respectfully,

A handwritten signature in black ink that reads "David Schechter".

David Schechter, US Marketing Leader, GARDASIL

GARDASIL is a registered trademark of Merck & Co., Inc.

^aUltraSafe Passive[®] delivery system is a registered trademark of Safety Syringes, Inc.